(Q34920191)

5 August 2017

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial (English)

1 reference

5 August 2017

0 references

0 references

1

Clive Ballard

1 reference

5 August 2017

Maria Luisa Hanney

2

1 reference

5 August 2017

Megan Theodoulou

3

1 reference

5 August 2017

Simon Douglas

4

1 reference

5 August 2017

Rupert McShane

5

1 reference

5 August 2017

Katja Kossakowski

6

1 reference

5 August 2017

Randeep Gill

7

1 reference

5 August 2017

Edmund Juszczak

8

1 reference

5 August 2017

Ly-Mee Yu

9

1 reference

5 August 2017

Robin Jacoby

10

1 reference

5 August 2017

DART-AD investigators

11

1 reference

5 August 2017

language of work or name

1 reference

8 January 2009

1 reference

5 August 2017

1 reference

5 August 2017

8

1 reference

5 August 2017

151-157

1 reference

5 August 2017

2

1 reference

Global prevalence of dementia: a Delphi consensus study

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Treating behavioural and psychological signs in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Hallucinations and associated factors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Neuroleptic drugs in dementia: benefits and harm

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Variation in Nursing Home Antipsychotic Prescribing Rates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Donepezil for the treatment of agitation in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970295-3

7 January 2021

10.1016/S1474-4422(08)70295-3

Identifiers

DOI

1 reference

5 August 2017

1 reference